New Multiple Sclerosis Drug Zinbryta Approved

Roni Shye
Roni Shye, PharmD BCGP BCACP, is a licensed pharmacist in the states of Florida, Ohio, and Pennsylvania.
Posted on

The Multiple Sclerosis Foundation estimates that more than 400,000 people in the United States have been diagnosed with MS. There is no cure for multiple sclerosis (MS), but there are treatments available that can slow down its progression or treat symptoms.

The FDA recently approved a new option for relapsing forms of multiple sclerosis: Zinbryta (daclizumab).

Is there anything unique about Zinbryta?

Yes. Zinbryta is the first once-monthly injection for MS that you can give to yourself at home.

There are other treatments available that are also used monthly, but they can’t be self-administered; they must be given to you by a health care practitioner. Other treatments you can use at home must be taken more often.

What are the advantages to self-adminstered injections like Zinbryta?

Convenience. Self-administration allows you to take the medication at a time that is best for you.

Many other MS medications require an infusion at your doctor’s office. That means you have to spend not only the time and transportation to and from the office, but the time to receive the infusion.

How will Zinbryta be available?
Zinbryta will be available in a single dose 150 mg/mL pre-filled syringe.

How will Zinbryta be used?

The recommended dose of Zinbryta is a 150 mg injection once a month. You’ll inject the medication subcutaneously (into the skin) into a few approved areas, including thighs, stomach, and the back of your upper arms.

What are the side effects of Zinbryta?

The most common side effects associated with Zinbryta are upper respiratory tract infections (common cold), rash, flu, skin inflammation, throat pain, eczema, and swelling of the lymph nodes.

When will Zinbryta be available?
Zinbryta was approved at the end of May 2016, and is expected be available in the third quarter of 2016.

Want more information?

See the press release from the manufacturer here, and the announcement from the FDA here.

Drugs featured in this story

Filed under